Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Lisinopril Include Objectives, Indications, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Contra Indications and Toxicity

Moni Theresa Tsappidi, Muralinath E., Srinivas G., Guruprasad M., Ramanjaneyulu D.V.

Abstract


For almost 30 years, lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, has been approved to treat hypertension and lessen cardiovascular stress. As a competitive ACE inhibitor, lisinopril inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This activity explains regarding lisinopril's mechanism of action, highlighting its distinct pharmacokinetic parameters and half-life compared to other ACE inhibitors. The FDA-approved indications, off-label usage, contraindications, drug-drug interactions, and possible toxicity of lisinopril are also covered. Besides, dosage recommendations, warnings, and necessary patient monitoring protocols are outlined to support safe administration. Along with lisinopril, this exercise also discusses the critical role that an interdisciplinary healthcare team plays in managing hypertension.


Full Text:

PDF

References


Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q., Xue, H., & Wright, J. M. (2018). First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews, 2018(11), CD008170. https://doi.org/10.1002/14651858.CD008170.pub3

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurray, J. J., Mitchell, J. E., Peterson, P. N., Riegel, B., ... Wilkoff, B. L. (2013). 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), 1810–1852. https://doi.org/10.1161/CIR.0b013e31829e8807

O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., Granger, C. B., Krumholz, H. M., Linderbaum, J. A., Morrow, D. A., Newby, L. K., Ornato, J. P., Ou, N., Radford, M. J., Tamis-Holland, J. E., ... Zhao, D. X. (2013). 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 61(4), e78–e140. https://doi.org/10.1016/j.jacc.2012.11.019

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., ... Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, 71(19), e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006

ACE Inhibitor Myocardial Infarction Collaborative Group. (1998). Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation, 97(22), 2202–2212. https://doi.org/10.1161/01.CIR.97.22.2202

Rout, P., & Jialal, I. (2025). Diabetic nephropathy. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482377/

Vlahakos, D. V., Marathias, K. P., Agroyannis, B., & Madias, N. E. (2003). Posttransplant erythrocytosis. Kidney International, 63(4), 1187–1194. https://doi.org/10.1046/j.1523-1755.2003.00824.x

Regulski, M., Regulska, K., Stanisz, B. J., Murias, M., Gieremek, P., Wzgarda, A., & Niznik, B. (2015). Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Current Pharmaceutical Design, 21(13), 1764–1775. https://doi.org/10.2174/1381612821666150302150354

Bezalel, S., Mahlab-Guri, K., Asher, I., Werner, B., & Sthoeger, Z. M. (2015). Angiotensin-converting enzyme inhibitor-induced angioedema. American Journal of Medicine, 128(2), 120–125. https://doi.org/10.1016/j.amjmed.2014.09.005

Warner, N. J., & Rush, J. E. (1988). Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs, 35(Suppl. 5), 89–97. https://doi.org/10.2165/00003495-198800355-00014


Refbacks

  • There are currently no refbacks.